Abgarmi ZM, Lotfi AS, Abroun S, Soleimani M, Ganji SM (2018) Inhibition of Erbb2 by trastuzumab induces oxidative stress markers in HER2 positive breast cancer cell lines. J Res Med Dental Sci 6(3):158–165

Google Scholar 

Ayob AZ, Ramasamy TS (2018) Cancer stem cells as key drivers of tumour progression. J Biomed Sci 25(1):20. https://doi.org/10.1186/s12929-018-0426-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23(10):1124

CAS  PubMed  Google Scholar 

Bayik D, Lathia JD (2021) Cancer stem cell–immune cell crosstalk in tumour progression. Nat Rev Cancer 21(8):526–536

CAS  PubMed  PubMed Central  Google Scholar 

Bomken S, Fišer K, Heidenreich O, Vormoor J (2010) Understanding the cancer stem cell. Br J Cancer 103(4):439–445

CAS  PubMed  PubMed Central  Google Scholar 

Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737

CAS  PubMed  Google Scholar 

Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3(2):224–237

CAS  PubMed  Google Scholar 

Burdick AD, Davis JW 2nd, Liu KJ, Hudson LG, Shi H, Monske ML, Burchiel SW (2003) Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Can Res 63(22):7825–7833

CAS  Google Scholar 

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676–3685

CAS  PubMed  Google Scholar 

Cahan P, Daley GQ (2013) Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol 14(6):357–368

CAS  PubMed  PubMed Central  Google Scholar 

Chakraborty S, Balan M, Flynn E, Zurakowski D, Choueiri TK, Pal S (2019) Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis 8(2):7. https://doi.org/10.1038/s41389-018-0116-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan AW, Tong JH, Chan SL, Lai PB, To KF (2014) Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 64(7):935–950. https://doi.org/10.1111/his.12342

Article  PubMed  Google Scholar 

Chen J (2014) Reactive oxygen species and drug resistance in cancer chemotherapy. Austin J Clin Pathol 1(4):1–7

CAS  Google Scholar 

Chen S, Zhao Y, Shen F, Long D, Yu T, Lin X (2019) Introduction of exogenous wild-type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor-κB in non-small cell lung cancer NCI-H1299 cells. Oncol Rep 41(3):2051–2059

CAS  PubMed  Google Scholar 

Chhikara BS, Parang K (2023) Global cancer statistics 2022: the trends projection analysis. Chem Biol Lett 10(1):451–451

Google Scholar 

Choi B-H, Kim JM, Kwak M-K (2021) The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. Arch Pharmacal Res 44(3):263–280

CAS  Google Scholar 

Clark DW, Palle K (2016) Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med 4(24):518–518. https://doi.org/10.21037/atm.2016.11.82

Article  CAS  PubMed  PubMed Central  Google Scholar 

Copple IM, Goldring CE, Kitteringham NR, Park BK (2008) The Nrf2–Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 246(1):24–33

CAS  PubMed  Google Scholar 

De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B et al (2011) High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica 96(10):1548–1551. https://doi.org/10.3324/haematol.2011.043786

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA et al (2020) Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol 235(4):3142–3156

CAS  PubMed  Google Scholar 

Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al (2009a) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780. https://doi.org/10.1038/nature07733

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al (2009b) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783. https://doi.org/10.1038/nature07733

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH (2002) Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via epidermal growth factor receptor. FASEB J 16(13):1–21

Google Scholar 

Dogan I, Cumaoglu A, Aricioglu A, Ekmekci A (2011) Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem 347:41–51

CAS  PubMed  Google Scholar 

Durko L, Wlodarski W, Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M, Hogendorf P et al (2017) Expression and clinical significance of cancer stem cell markers CD24, CD44, and CD133 in pancreatic ductal adenocarcinoma and chronic pancreatitis. Dis Markers. https://doi.org/10.1155/2017/3276806

Article  PubMed  PubMed Central  Google Scholar 

Fattahi M, Sheervalilou R, Hoseinpour N, Valiloo M, Pedram N, Montazeri V et al (2020) The correlation between twist 1 and 2 promoter methylation status and clinicopathologic characteristics of patients with breast cancer. Gene Rep 20:100741

CAS  Google Scholar 

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013–e180013

PubMed  PubMed Central  Google Scholar 

Fulawka L, Donizy P, Halon A (2014) Cancer stem cells–the current status of an old concept: literature review and clinical approaches. Biol Res 47(1):66

PubMed  PubMed Central  Google Scholar 

Gianni D, Taulet N, DerMardirossian C, Bokoch GM (2010) c-Src–mediated phosphorylation of NoxA1 and Tks4 induces the reactive oxygen species (ROS)–dependent formation of functional invadopodia in human colon cancer cells. Mol Biol Cell 21(23):4287–4298

CAS  PubMed  PubMed Central  Google Scholar 

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567

CAS  PubMed  PubMed Central  Google Scholar 

Halliwell B (2007) Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death. Free radicals in biology and medicine, 187–267.

Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N et al (2009) Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15(10):3423–3432. https://doi.org/10.1158/1078-0432.ccr-08-2822

Article  CAS  PubMed  Google Scholar 

Islam SS, Uddin M, Noman ASM, Akter H, Dity NJ, Basiruzzman M et al (2019) Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1. EBioMedicine 43:211–224

PubMed  PubMed Central  Google Scholar 

Jung B-J, Yoo H-S, Shin S, Park Y-J, Jeon S-M (2018) Dysregulation of NRF2 in cancer: from molecular mechanisms to therapeutic opportunities. Biomol Ther 26(1):57

CAS  Google Scholar 

Kahroba H, Shirmohamadi M, Hejazi MS, Samadi N (2019) The Role of Nrf2 signaling in cancer stem cells: from stemness and self-renewal to tumorigenesis and chemoresistance. Life Sci 239:116986

CAS  PubMed  Google Scholar 

Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z (2017) Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res 23(4):793–802. https://doi.org/10.1007/s12253-016-0169-z

Article  CAS  PubMed  Google Scholar 

Kapucuoğlu N, Bozkurt KK, Başpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, Akçil M (2015) The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol-Res Pract 211(10):740–747

PubMed  Google Scholar 

Kensler TW, Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31(1):90–99. https://doi.org/10.1093/carcin/bgp231

Article  CAS  PubMed  Google Scholar 

Khodabandeh Z, Valilo M, Velaei K, Pirpour Tazehkand A (2022) The potential role of nicotine in breast cancer initiation, development, angiogenesis, invasion, metastasis, and resistance to therapy. Breast Cancer 29(5):778–789

PubMed  Google Scholar 

Kim KH, Kang YJ, Jo JO, Ock MS, Moon SH, Suh DS et al (2014) DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers. Biochem Biophys Res Commun 447(2):315–322. https://doi.org/10.1016/j.bbrc.2014.03.144

Article  CAS  PubMed  Google Scholar 

Kim R, Kim SB, Cho EH, Park SH, Park S